WHAT IS
HIFU THERAPY?
HIFU — High-Intensity Focused Ultrasound — converges hundreds of ultrasound beams onto a single point inside the body, generating temperatures above 65°C at the focal point to destroy tissue with surgical precision and zero incisions.
analyticsAt a Glance
- check_circleNo incisions, no radiation, no anaesthesia required in most applications — truly non-invasive ablation
- check_circleApproved or routinely used for uterine fibroids, prostate cancer, liver tumours, bone metastases, and pancreatic cancer
- check_circleTwo main clinical systems: MRgFUS (MRI-guided) and USgHIFU (ultrasound-guided) — suited to different applications
- check_circleWidely available at specialist centres in China and accessible to international patients via CancerFax
What Is HIFU and How Is It Different from Other Ablation Treatments?
All ablation therapies — cryoablation, RFA, MWA, and HIFU — destroy tumour tissue in place rather than removing it surgically. What makes HIFU unique is that the energy source never touches the body. No needles, no probes, no electrodes are inserted. The focused ultrasound beam passes through skin and intervening tissue without causing damage — all of its energy is released only at the precise focal point inside the tumour.
“HIFU is the closest thing oncology has to what science fiction imagined surgery would look like — a beam of energy aimed at a tumour from outside the body, destroying it from within.”
How HIFU Is Truly Non-Invasive
A transducer positioned against the skin (or inserted transrectally for prostate HIFU) emits hundreds of ultrasound beams that individually pass harmlessly through tissue. They converge precisely at the target point, where their combined energy generates heat above 65°C — instantly coagulating tissue proteins. Everything outside the focal point remains unaffected.
HIFU vs Other Ablation Modalities
Cryoablation, RFA, and MWA all require probe insertion through the skin or a surgical incision to reach the tumour. HIFU requires no penetration of the body surface. This eliminates probe-tract bleeding, infection, and organ laceration risks — and means HIFU can treat some lesions that percutaneous ablation cannot safely access.
HIFU in Numbers
Key technical and clinical parameters that define how HIFU works and its current clinical reach.
- 65–85°CTemperature at the HIFU focal pointProtein coagulation and immediate cell death occur above 56°C; HIFU focal temperatures of 65–85°C ensure reliable instantaneous tissue destruction.
- 1–3 mmDiameter of a single HIFU focal lesionEach focal spot is approximately 1–3 mm in diameter; the transducer moves in a grid pattern across the treatment volume to ablate the full tumour.
- 1 million+HIFU procedures performed globallyEstimated cumulative global HIFU procedures across all approved indications — predominantly uterine fibroids, prostate cancer, and bone metastasis pain relief.
- 0Incisions required for external HIFUExternal transcutaneous HIFU requires no skin cuts, no probes, and no general anaesthesia — enabling outpatient treatment in most uterine fibroid and bone applications.
HIFU System Types: MRgFUS vs USgHIFU
Two guidance platforms dominate clinical HIFU practice — each with distinct strengths, clinical applications, and infrastructure requirements.
| Feature | MRgFUS (MRI-Guided) | USgHIFU (Ultrasound-Guided) |
|---|---|---|
| Imaging guidance | Real-time MRI with thermometry — measures temperature at focal point continuously | Diagnostic ultrasound — visualises treatment zone but cannot measure temperature directly |
| Temperature monitoring | MR thermometry provides real-time focal temperature maps | Indirect — operator infers thermal dose from tissue echogenicity changes |
| Primary applications | Uterine fibroids (ExAblate), brain tumours, essential tremor, breast fibroadenoma | Liver, pancreas, kidney, bone metastases, uterine fibroids (HAIFU, Chongqing system) |
| Patient position | Inside MRI scanner bore — claustrophobia a limiting factor for some patients | On open treatment couch — more accessible and less confining |
| Session duration | 2–4 hours (fibroid); 1–2 hours (focal ablation) | 45–120 minutes depending on tumour volume |
| Infrastructure cost | Very high — requires MRI scanner integration | Moderate — standalone ultrasound-guided system |
| Availability in China | Selected major centres (ExAblate, InSightec) | Widely available — Chinese-manufactured systems (HAIFU, SuperSonic) in routine use at 200+ centres |
| Key commercial systems | InSightec ExAblate Neuro / Body; Profound Medical Tulsa-PRO (prostate) | HAIFU (Chongqing), SuperSonic Imagine, Theraclion, Mianyang Sonic Tech |
What Conditions Is HIFU Used For?
HIFU has regulatory approval or established clinical use across a broad range of indications — both oncological and benign.
Uterine Fibroids — MRgFUS and USgHIFU
The most widely performed HIFU application globally. MRgFUS is FDA/CE-approved for symptomatic uterine fibroids — providing uterus-preserving, same-day treatment with immediate return to activity. Chinese USgHIFU systems (HAIFU) treat hundreds of thousands of fibroid patients annually.
Prostate Cancer — Focal and Whole-Gland
HIFU delivers precise ablation of prostate tissue transrectally — either targeting only the cancer-bearing zone (focal HIFU) or the entire gland (whole-gland HIFU). It is CE-marked in Europe and widely used in China as a curative-intent alternative to surgery and radiotherapy for localised prostate cancer.
Liver, Pancreas, and Kidney Tumours
USgHIFU is used at Chinese centres for unresectable HCC, pancreatic cancer pain palliation, and renal cell carcinoma — delivered transcutaneously with the patient submerged in a water bath or coupling gel. Particularly valuable in patients who cannot tolerate surgical or percutaneous ablation.
Bone Metastases — Pain Palliation
MRgFUS for bone metastasis pain is FDA-approved (ExAblate 2100 Bone system) — delivering durable pain relief in 64–72% of patients with a single outpatient treatment session, without radiation exposure or systemic toxicity.
Benefits vs Limitations of HIFU
HIFU's non-invasive nature is a genuine clinical advantage — but it comes with important constraints around tissue access, monitoring, and the depth and size of lesions that can be treated.
Benefits
- Truly non-invasive — no skin punctureNo infection risk, no bleeding from probe insertion, no general anaesthesia in most applications. Most patients resume normal activity within 24–48 hours.
- Repeatable without cumulative dose limitUnlike radiotherapy, HIFU has no radiation dose ceiling — the same lesion can be re-treated at recurrence, and new lesions at different sites can be treated independently.
- Preserves surrounding anatomyFocal precision spares nerves, vessels, and organs immediately adjacent to the treated volume — critical for prostate HIFU where continence and erectile function preservation are primary goals.
- Same-day or outpatient for most indicationsUterine fibroid, bone metastasis, and many prostate HIFU treatments are completed as outpatient procedures with patients discharged within hours.
Limitations
- Requires clear acoustic windowBowel gas, bone, surgical clips, and implants all block or distort ultrasound. Tumours behind ribs, in the pelvis, or near bowel loops may not be safely accessible.
- Deep lesions and large volumes need multiple sessionsEach focal spot is 1–3 mm — treating a 5 cm tumour requires thousands of focal points moved methodically across the volume, making treatment of large tumours time-consuming.
- Limited evidence for some oncological applicationsFor liver, pancreatic, and kidney cancer, the evidence base is predominantly single-arm series from Chinese centres — less mature than the fibroid or bone metastasis pain data.
- MRgFUS requires claustrophobia toleranceMRI-guided HIFU requires the patient to remain still inside an MRI scanner bore for 2–4 hours — challenging for claustrophobic or anxious patients.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the physics to disease-specific applications and access in China.
- HIFU Therapy — Complete Treatment Guide
- HIFU Physics: How Acoustic Focusing Destroys Tissue
- HIFU for Uterine Fibroids: MRgFUS Complete Guide
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
- HIFU for Liver Cancer: HCC and Liver Metastases
- HIFU for Bone Metastases: Pain Palliation and Local Control
Frequently Asked Questions
Common questions from patients encountering HIFU for the first time.
Basics of HIFU
Is HIFU painful during the procedure?
This depends on the application. Uterine fibroid HIFU typically causes mild pelvic cramping or warmth — managed with oral analgesics and sedation. Prostate HIFU is performed under spinal or general anaesthesia, so patients feel nothing during the procedure. Bone metastasis HIFU may cause transient localised pain during treatment that is managed with IV analgesia. For liver and pancreatic HIFU, patients lie in a water bath and receive IV sedation — discomfort is generally mild to moderate and well-managed by the treating team.
How do I know if the tumour was completely treated by HIFU?
Post-treatment MRI or contrast-enhanced ultrasound is performed — usually on the same day or within 24 hours — to assess the non-perfused volume (NPV): the proportion of the treated lesion that no longer shows contrast enhancement, indicating successful ablation. An NPV ratio above 80–90% is the standard technical success criterion. Follow-up imaging at 1 month and 3 months confirms durability of the ablation and rules out residual or recurrent viable tumour.
Can HIFU be used if I have a pacemaker or metal implants?
For MRgFUS, a pacemaker or MRI-incompatible metal implant is a contraindication — the MRI component of the system cannot be used safely. For USgHIFU, pacemakers are generally not a contraindication to the focused ultrasound itself, but the treating team must confirm that the implant is not in or near the acoustic beam path. Metal implants between the transducer and the target (such as surgical clips near the liver or a hip prosthesis near the pelvis) can cause acoustic shadowing that impedes treatment — this is assessed during pre-procedure planning imaging.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could HIFU Be Right for Your Condition?
CancerFax reviews your imaging and clinical history to assess whether HIFU is appropriate — and connects you with specialist HIFU centres in China and India with the system and expertise suited to your specific tumour type and location.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.